THIS AGREEMENT ON DEVELOPMENT OF THE SYNTHESIS OF FC-1271A AND MANUFACTURING OPTIONDevelopment and Manufacturing Agreement • April 4th, 2006 • Quatrx Pharmaceuticals Co • Pharmaceutical preparations
Development and manufacturing agreement: customer versionDevelopment and Manufacturing Agreement • December 19th, 2019
ImaginAb, CPDC enter into an agreementDevelopment and Manufacturing Agreement • September 21st, 2021
Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and is of the type that the registrant treats as private and confidential. Credo Technology Group Development...Development and Manufacturing Agreement • January 3rd, 2022 • Credo Technology Group Holding LTD • Semiconductors & related devices • California
This Development and Manufacturing Agreement, dated as of the last signature below (the "Agreement"), is entered into by and among Credo Technology (HK) Limited (“Credo”) having its office at Unit 221 2/F, Core Building 2, Phase 1, #1 Science Park West Ave, Hong Kong Science Park, Pak Shek Kok, N.T. Hong Kong ("Credo"), and BizLink Technology, Inc., a California corporation having its office at 47211 Bayside Parkway, Fremont, CA 94538 (“BizLink” and, together, the "Parties", and each, a "Party").
DEVELOPMENT AND MANUFACTURING AGREEMENTDevelopment and Manufacturing Agreement • November 21st, 2014 • Viveve Medical, Inc. • Electromedical & electrotherapeutic apparatus • California
This Development and Manufacturing Agreement (the "Agreement") is made and entered into as of 12 day of June 2006 (the "Effective Date") by and between Stellartech Research Corporation ("Stellartech"), a California corporation with a principal place of business at 1346 Bordeaux Drive, Sunnyvale, CA 94089, and TiVaMed, Inc. ("Company"), a Delaware Corporation with a principal place of business at 900 Welch Road, Palo Alto, California 94304 (each referred to below as a "party" or collectively as the "parties").
AMENDMENT NO. 1 TO DEVELOPMENT AND MANUFACTURING AGREEMENTDevelopment and Manufacturing Agreement • June 22nd, 2009 • Cornerstone Therapeutics Inc • Pharmaceutical preparations • New York
This Amendment No. 1 to Development and Manufacturing Agreement (this “Amendment”) is dated June 16, 2009 (the “Amendment Date”), by and between Cornerstone BioPharma, Inc. a Nevada corporation with its principal offices located at 1255 Crescent Green Drive, Suite 250, Cary, NC 27518 (“Company”), NEOS Therapeutics, L.P., a Texas limited partnership (“Manufacturer”) with its principal offices located at 2940 N. Hwy. 360, Suite 100, Grand Prairie, TX 75050 and Coating Place, Inc., a Wisconsin corporation (“Supplier”) with its principal offices located at 200 Paoli Street, P.O. Box 930310, Verona, WI, 53593. Manufacturer, Supplier and Company sometimes are referred to herein individually as a “Party” and collectively as the “Parties.”
DealdocDevelopment and Manufacturing Agreement • July 22nd, 2024
Development and manufacturing agreement for integrated cerebral oximetry and continuous non-invasive blood pressure in a single platform
DEVELOPMENT and MANUFACTURING AGREEMENT This Agreement is made and entered into this 15th day of August, 2007, by and between Startale Group Inc., a Nevada corporation, having its principal office at 4320 Winfield Road, Suite 200 Warrenville, Illinois...Development and Manufacturing Agreement • October 2nd, 2007 • Startale Group Inc. • Nevada
THIRD AMENDED AND RESTATED DEVELOPMENT AND MANUFACTURING AGREEMENTDevelopment and Manufacturing Agreement • February 2nd, 2012 • Plantronics Inc /Ca/ • Telephone & telegraph apparatus • California
This THIRD AMENDED AND RESTATED Development Manufacturing Agreement (this "Agreement") is made and entered into as of October 15, 2011 (the “Effective Date”) between: PLANTRONICS B.V., a Netherlands corporation, with principal offices at Southpoint, Building C, Scorpius 140, 2132 LR Hoofddorp, the Netherlands ("Plantronics") and, for certain limited purposes as set forth herein Plantronics Communications Technology (Suzhou) Co. Ltd. (“Plantronics PCH”), and GoerTek, Inc. , a Chinese business entity , acting on behalf of itself and its Affiliates, with its principal place of business located at No. 268 Dong Fank Road; Hi Tech Industry Development District; Wei Fang, Shandong 266031. (“GoerTek ”).
NOTE: Portions of this Exhibit are the subject of a Confidential Treatment Request by the Registrant to the Securities and Exchange Commission (the “Commission”). Such portions have been redacted and are marked with a “[***]” in place of the redacted...Development and Manufacturing Agreement • August 16th, 2004 • Nanogen Inc • Laboratory analytical instruments • New Jersey
THIS DEVELOPMENT AND MANUFACTURING AGREEMENT (the “Agreement”) is executed as of this 9th day of October, 2001, by and between PRINCETON BIOMEDITECH CORPORATION, a New Jersey corporation (“PBM”), having its principal place of business at 4242 U.S. Route 1, Monmouth Junction, New Jersey 08852, and SYN.X PHARMA, INC., an Ontario corporation (“SYN.X”), having its principal place of business at 6354 Viscount Road, Mississauga, Ontario L4VIH3 Canada. PBM and SYNX are individually referred to herein as a “Party” and collectively referred to herein as the “Parties”.
ContractDevelopment and Manufacturing Agreement • August 15th, 2008 • Neurologix Inc/De • Pharmaceutical preparations
SECOND AMENDMENT TO AMENDED AND RESTATED DEVELOPMENT AND MANUFACTURING AGREEMENTDevelopment and Manufacturing Agreement • May 9th, 2013 • Cornerstone Therapeutics Inc • Pharmaceutical preparations
THIS SECOND AMENDMENT TO AMENDED AND RESTATED DEVELOPMENT AND MANUFACTURING AGREEMENT (“Second Amendment”) is made and entered into this 27th day of February, 2013 (“Second Amendment Effective Date”) by and between BAXTER HEALTHCARE CORPORATION, a Delaware corporation (“Baxter”), and CORNERSTONE THERAPEUTICS, a Delaware corporation (“Cornerstone”).
DEVELOPMENT AND MANUFACTURING AGREEMENTDevelopment and Manufacturing Agreement • May 13th, 2005 • Neurologix Inc/De • Pharmaceutical preparations • Minnesota
THIS DEVELOPMENT AND MANUFACTURING AGREEMENT (this "Agreement") is made and entered into as of April 27, 2005 ("Effective Date"), by and among Neurologix, Inc., a Delaware corporation and Neurologix Research, Inc., a Delaware corporation (collectively "Neurologix") and Medtronic, Inc., a Minnesota corporation ("Medtronic"). Each of the above is sometimes referred to herein individually as a "Party" and collectively as the "Parties."
Development and Manufacturing AgreementDevelopment and Manufacturing Agreement • November 6th, 2017 • Hancock Jaffe Laboratories, Inc. • Surgical & medical instruments & apparatus
This Development and Manufacturing Agreement (the “Agreement”) is made and entered into on this 1st day of February, 2013, by and between Hancock Jaffe Laboratories Aesthetics, Inc. (“HJLA”), a Delaware corporation having a business address at 70 Doppler, Irvine, California and Hancock Jaffe Laboratories, Inc. (the “Company”), a Delaware corporation.
DEVELOPMENT AND MANUFACTURING AGREEMENTDevelopment and Manufacturing Agreement • September 9th, 2004 • Dragon Pharmaceuticals Inc • Pharmaceutical preparations
Dragon Pharmaceutical, Inc., a corporation duly incorporated under the laws of the state of Florida, USA, having an office at 1900-1055 West Hastings St., Vancouver, British Colombia, Canada, and duly licensed to do business there.
AGREEMENTDevelopment and Manufacturing Agreement • November 14th, 2006 • Interpharm Holdings Inc • Pharmaceutical preparations • New York
THIS AGREEMENT is made and entered into as of this 4th day of October, 2006, by and between Interpharm, Inc., having its principal place of business at 75 Adams Avenue, Hauppauge, New York, 11788 (“Interpharm”), and Tris Pharma, Inc. having its principal place of business at 2033 Route 130, Suite D, Monmouth Junction, NJ 08852 (“Tris”).
SECOND AMENDMENT TO DEVELOPMENT AND MANUFACTURING AGREEMENTDevelopment and Manufacturing Agreement • November 10th, 2015 • Surgiquest Inc • Surgical & medical instruments & apparatus
This Second Amendment to Development and Manufacturing Agreement (this “First Amendment”) is made as of December 15th, 2014 (“Second Amendment Effective Date”) by and among W.O.M. World of Medicine, GmbH, a German corporation with a place of business at Salzufer 8, 10587 Berlin (“WOM Germany”), W.O.M. World of Medicine, USA, a Florida corporation with a place of business at 4531 36th St., Orlando, FL 32801 (“WOM USA,” and together with WOM Germany, “WOM”) and SurgiQuest, Inc., a Delaware corporation with its principal place of business at 333 Quarry Road Milford, CT 06460 (“SurgiQuest”).
CELL THERAPY DEVELOPMENT, MANUFACTURING AND/OR TISSUE PROCESSING TERMS AND CONDITIONS BETWEEN WuXi AppTec, Inc. and NewLink Genetics CorporationDevelopment and Manufacturing Agreement • August 5th, 2014 • Newlink Genetics Corp • Pharmaceutical preparations • New York
This Development and Manufacturing Terms and Conditions (the “Agreement”) is made and entered into as of the date of the last signature on the signature page hereto (the “Effective Date”) by and between WuXi AppTec, Inc., a corporation organized under the laws of Delaware with offices located at 4751 League Island Blvd., Philadelphia, PA 19112 (“WuXi AppTec”), and NewLink Genetics Corporation, a company organized under the laws of Delaware with offices located at 2503 South Loop Drive, Suite 5100, Ames, IA 50010 and Affiliates (“Customer”). Customer and WuXi AppTec are referred to herein individually as a “Party” and collectively as the “Parties”.
Biotecnol SA AndDevelopment and Manufacturing Agreement • March 31st, 2006 • Idm Pharma, Inc. • Pharmaceutical preparations
Development and Manufacturing AgreementDevelopment and Manufacturing Agreement • August 1st, 2008 • Sulphco Inc • Oil & gas field services, nec • Texas
SulphCo is engaged in the business of commercializing its patented and proprietary SonocrackingTM process. The SonocrackingTM process is designed to use high power ultrasound to modify the composition and structure of crude oil derived from any source (e.g.,normal crude oil production, tar sands, shale, etc.) and/or crude oil fractions (e.g., diesel, kerosene, etc.), including, without limitation, the upgrading of crude oil and fractions thereof by lowering the density, lowering the viscosity and reducing the sulfur-containing, nitrogen-containing, acid-containing and other undesirable components of crude oil and its fractions. Among the benefits of this upgrading of crude oil is the transformation of sour heavy crude oils into sweeter, lighter crudes, producing more gallons of usable oil per barrel. For purposes of this Agreement, SulphCo’s“Primary Field of Business” shall include (i) the foregoing applications, together with any future benefits yet to be discovered that may be derive
DEVELOPMENT AND MANUFACTURING AGREEMENTDevelopment and Manufacturing Agreement • April 22nd, 2005 • Icop Digital, Inc • Radio & tv broadcasting & communications equipment • New York
This Development and Manufacturing Agreement dated February 10, 2005, is entered into by ICOP DIGITAL, INC., a corporation organized and existing under the laws of the State of Colorado with its principal place of business located at 11011 King Street, Suite 260, Overland Park, KS 66210, USA (“ICOP DIGITAL”), and TIETECH CO., LTD, a corporation organized and existing under the laws of Japan with its principal business address at 2-13-1, Chikama-dori, Minami-ku, Nagoya, Aichi, Japan 457-0071 (“TIETECH”) and, each of whom is individually referred to as a “Party” and both of whom are sometimes collectively referred to as “Parties.”
Anthos Therapeutics Partners with Lonza to Develop and Manufacture Abelacimab (MAA868), a Unique Dual Factor XI / XIa inhibitorDevelopment and Manufacturing Agreement • June 10th, 2020
The agreement furthers Anthos Therapeutics mission to develop Abelacimab for patients at risk of thrombotic events, which are currently underserved by conventional anti-coagulant therapies.
SECOND AMENDED AND RESTATED DEVELOPMENT AND MANUFACTURING AGREEMENT Between PLANTRONICS B.V. and GOERTEK, INC. *** Certain information in this Agreement has been omitted and filed separately with the Securities and Exchange Commission. Confidential...Development and Manufacturing Agreement • May 26th, 2009 • Plantronics Inc /Ca/ • Telephone & telegraph apparatus • California
This SECOND AMENDED AND RESTATED DEVELOPMENT MANUFACTURING AGREEMENT (this "Agreement") is made and entered into as of March 20, 2009 (the “Effective Date”) between: PLANTRONICS B.V., a Netherlands corporation, with principal offices at Southpoint, Building C, Scorpius 140, 2132 LR Hoofddorp, the Netherlands ("Plantronics") and, for certain limited purposes as set forth herein Plantronics Communications Technology (Suzhou) Co. Ltd. (“Plantronics PCH”), and GoerTek, Inc. , a Chinese business entity , acting on behalf of itself and its Affiliates, with its principal place of business located at No. 268 Dong Fank Road; Hi Tech Industry Development District; Wei Fang, Shandong 266031. (“GoerTek ”).
Marsha G. Prokop Baxter Healthcare Corporation Director, Contract Management 25212 W. Illinois Route 120 (WG2-3S) BioPharma Solutions Round Lake, Illinois 60073 Tel: 847.270.5250Development and Manufacturing Agreement • May 9th, 2013 • Cornerstone Therapeutics Inc • Pharmaceutical preparations
ImmuCell CorporationDevelopment and Manufacturing Agreement • August 16th, 2010 • Immucell Corp /De/ • In vitro & in vivo diagnostic substances • Delaware
Confidential Treatment as to certain portions has been requested, which portions have been omitted and filed separately with the Securities and Exchange Commission
Lonza enters development and manufacturing agreement with Genmab A/S for a novel antibody drug conjugate (ADC), HuMax-TF™Development and Manufacturing Agreement • October 25th, 2011
This agreement secures a development and cGMP manufacturing plan for Genmab A/S, a biotechnology company engaged in the development of human antibody therapeutics for the potential treatment of cancer
DEVELOPMENT AND MANUFACTURING AGREEMENT THIS AGREEMENT is made on the day of 2005 (Effective Date) BETWEENDevelopment and Manufacturing Agreement • October 13th, 2005 • Capacitive Deionization Technology Systems Inc • Water supply • Texas
Memo Therapeutics AG and Northway Biotechpharma sign a Development and Manufacturing AgreementDevelopment and Manufacturing Agreement • June 25th, 2020
Zurich, Switzerland, and Vilnius, Lithuania – June 25, 2020 – Memo Therapeutics AG and Northway Biotechpharma, a leading biopharmaceutical Contract Development and Manufacturing Organization (CDMO), have signed a Development and Manufacturing Agreement for a therapeutic antibody.
CONFIDENTIAL GPEx® DEVELOPMENT AND MANUFACTURING AGREEMENTDevelopment and Manufacturing Agreement • July 9th, 2018 • Vaccinex, Inc. • Pharmaceutical preparations • New York
This GPEx® Development and Manufacturing Agreement (“Agreement”) is made as of January 13, 2010 (“Effective Date”), by and between Vaccinex, Inc., a with a place of business at 1895 Mt. Hope Avenue, Rochester, NY 14620, USA (“Vaccinex”) and Catalent Pharma Solutions, LLC, a Delaware limited liability company, with a place of business at 14 Schoolhouse Road, Somerset, New Jersey 08873, USA (“Catalent”).
DEVELOPMENT AND MANUFACTURING AGREEMENTDevelopment and Manufacturing Agreement • November 30th, 2012 • AVRA Surgical Robotics, Inc. • Blank checks
This Development and Manufacturing Agreement (“Agreement”) is made and entered into as of the ___ day of October, 2012, by and between MIS-Robotics GmbH, a German corporation with offices at Am Technologiepark 12, 82229 Seefeld, HRB 200457 Amtsgericht München (“MIS”), and RG Mechatronics GmbH, a German corporation with offices at Am Technologiepark 12, 82229 Seefeld, HRB 172994 Amtsgericht München (“RGM”).
DEVELOPMENT AND MANUFACTURING AGREEMENTDevelopment and Manufacturing Agreement • September 29th, 2003 • Palatin Technologies Inc • Pharmaceutical preparations
BY AND BETWEEN: Palatin Technologies, Inc., a Delaware corporation, having an address of 4-C Cedar Brook Drive, Cedar Brook Corporate Center, Cranbury, NJ 08512 (hereinafter referred to as "Palatin");
Date ReferenceDevelopment and Manufacturing Agreement • May 11th, 2016
THIRD AMENDMENT TO DEVELOPMENT AND MANUFACTURING AGREEMENTDevelopment and Manufacturing Agreement • May 14th, 2008 • Icop Digital, Inc • Radio & tv broadcasting & communications equipment
THIS THIRD AMENDMENT TO DEVELOPMENT AND MANUFACTURING AGREEMENT is made this 26th day of March, 2008, by and among ICOP DIGITAL, INC., a Colorado Corporation, (“ICOP DIGITAL”) and the TIETECH CO., LTD., a Japanese Corporation, (“TIETECH”).
DEVELOPMENT AND MANUFACTURING AGREEMENTDevelopment and Manufacturing Agreement • November 5th, 2008 • Cornerstone Therapeutics Inc • Pharmaceutical preparations • New York
THIS DEVELOPMENT AND MANUFACTURING AGREEMENT (this “Agreement”) is made effective the 27th day of February, 2008, among Cornerstone BioPharma, Inc., a Delaware corporation (“Company”), NEOS Therapeutics, L.P., a Texas limited partnership (“Manufacturer”) and Coating Place, Inc., a Wisconsin corporation (“Supplier”). Manufacturer, Supplier, and Company are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
CONFIDENTIAL MATERIAL OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. DEVELOPMENT AND MANUFACTURING AGREEMENTDevelopment and Manufacturing Agreement • March 20th, 2009 • Icop Digital, Inc • Radio & tv broadcasting & communications equipment • Kansas
This Development and Manufacturing Agreement (“Agreement”) dated November 5, 2008, is entered into by ICOP DIGITAL, INC., a corporation organized and existing under the laws of the State of Kansas with its principal place of business located at 16801 West 116th Street, Lenexa, KS 66219, USA (“ICOP DIGITAL”), and EVERFOCUS ELECTRONICS CORPORATION, a corporation organized and existing under the laws of Taiwan with its principal business address at 12F, No. 79, Sec. 1, Shin-Tai Wu Road, Hsi-Chi, Taipei Hsien, Taiwan, R.O.C.; and at 1801 Highland Ave. Unit A, Duarte, CA 91010 USA (“EVERFOCUS”) and, each of whom is individually referred to as a “Party” and both of whom are sometimes collectively referred to as “Parties.”
